| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
10-30-2012, 05:24 AM
|
#1 | ||
|
|||
|
Junior Member
|
Remember "rember"? Data released in 2008 from Phase II trials involving 321 patients with mild and moderate Alzheimer’s disease revealed a 80% - 90% reduction in the rate of disease progression over two years in mild-moderate Alzheimer’s patients.
Well, the improved second generation rember is called LMTX and this is about to go into Phase 3 clinical trials! Saw this exciting news: Announcing a New Era in Alzheimer’s The Time for Tau Is Now as Phase 3 clinical trials get under way with a second-generation Tau Aggregation Inhibitor (TAI) aimed at halting the progression of Alzheimer’s · Event: Live Press Conference / Webinar in Conjunction with the 5th Clinical Trials Conference on Alzheimer’s Disease · Speaker: Professor Claude Wischik, Co-founder and Chairman of TauRx Therapeutics Ltd · Date: Tuesday, 30th October 2012 · Time: 16:00 – 16:45 Monte Carlo (Central European Time) / 15:00-15:45 London (GMT) 11:00-11:45 am NYC (EST) / 8:00-8:45 am Los Angeles (PST) To register for the free Webinar by TauRx Chairman Prof Claude Wischik: http://www.dontforgetalzheimers.com/ You can get video/audio on demand and the pdf slides if you miss the webinar. 
|
||
|
 Reply With Quote
|
| "Thanks for this!" says: | sim00 (11-01-2012) |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| TauRX - LMTX - PD ? | Parkinson's Disease | |||
| TauRx Pharmaceuticals | Parkinson's Disease | |||
TauRx - Announcing a New Era in Alzheimer’s
Threaded Mode